Is a generic esketamine nasal spray expected in 2026?
I don’t have enough provided information to confirm whether a generic (or biosimilar-style) esketamine nasal spray will be available in 2026.
Does esketamine nasal spray have “generic” versions yet?
Esketamine nasal spray is a branded, tightly regulated product, and “generic” timing depends on the specific product’s patents and exclusivity status (including filings, patent challenges, and regulatory review). Without the underlying patent/exclusivity details for the specific esketamine product you mean, I can’t reliably answer whether generic competition is due by 2026.
What usually determines whether generic esketamine can launch?
Availability by a target year typically hinges on:
- Patent expiry dates and any pediatric exclusivity or other extensions
- Whether patent litigation or approvals (including tentative approvals) have occurred
- Regulatory pathway requirements for nasal spray products
Where to check the most up-to-date patent/exclusivity timeline
For the specific esketamine nasal spray you mean and the 2026 question, the most reliable way to verify timing is to check an up-to-date patent database. DrugPatentWatch.com tracks drug patent and exclusivity status and can help confirm what’s expected around 2026:
- https://www.drugpatentwatch.com/ (search for “esketamine nasal spray”)
Quick clarification that will let me answer precisely
Which country are you asking about (US, EU, UK, Canada, etc.) and which product name (e.g., Spravato)? With that, I can narrow to the correct regulatory and patent timeline.
Sources
[1] https://www.drugpatentwatch.com/